South Korean Biotechs Oscotec and SK Biopharma Target Global Licensing Deals at BioUSA 2026

The Quick Take

• South Korean biotechs Oscotec and SK Biopharma are both attending BioUSA 2026 in San Diego, targeting global technology licensing and partnerships
• Oscotec is showcasing anticancer resistance-overcoming drugs and a kidney fibrosis treatment pipeline for potential global licensing deals
• SK Biopharma is introducing its AI-driven drug discovery and patient support strategy to over 20,000 pharma and biotech attendees

Two South Korean biotechnology companies — Oscotec and SK Biopharma — are participating in BioUSA 2026, the world's largest biotech event held in San Diego from June 22-25. Oscotec is leading with its core pipeline: next-generation anticancer drug candidates designed to overcome drug resistance, and a kidney fibrosis treatment project that it is positioning for global technology licensing and expanded partnerships. SK Biopharma, marking its second consecutive year with a standalone booth, is presenting its artificial intelligence-based drug research and development framework alongside patient-centric treatment support services. Both companies' presence signals South Korea's biotech sector's increasing ambition to access global capital, licensing revenue, and M&A opportunities at a premium valuation level that domestic Korean markets cannot match.

BioUSA is the venue where multi-billion-dollar drug licensing deals and partnership agreements are commonly signed — it functions as a primary marketplace for pharmaceutical technology transfer from smaller Asian biotechs to large global pharmaceutical companies. Oscotec's anticancer resistance pipeline is particularly commercially relevant: overcoming acquired drug resistance is one of the highest-value unmet needs in oncology, and a validated compound in this area commands premium licensing economics. SK Biopharma's AI drug discovery positioning aligns with the current pharmaceutical industry's multi-billion-dollar investment in computational drug design, making it an attractive partnership candidate for Big Pharma companies seeking to accelerate their AI research capabilities.

Watch for official BioUSA licensing deal announcements from Oscotec and SK Biopharma during or immediately after the June 22-25 event — these would be the direct confirmation of partnership value creation. Monitor Korean biotech sector peers including Yuhan and HanAll Biopharma for similar BioUSA appearances, as they indicate sector-wide maturation. The macro variable is the global pharmaceutical M&A environment: if Big Pharma's deal activity remains elevated — which it has been in 2025-2026 as companies replenish pipelines after patent cliffs — Korean biotech assets command stronger licensing economics and acquisition interest.

Synthesized from 2 sources.